Identifying novel druggable targets and repurposable drugs for premature ovarian insufficiency by integrated multiomics and causal inference analysis.
Key claim: Integrated multiomics Mendelian randomization identified seven high-confidence causal protein targets for premature ovarian insufficiency, with EPHA4, FSTL3, and NUCB2 validated in cisplatin-induced granulosa-cell models and computational docking supporting drug-repurposing opportunities such as cycloheximide–EPHA4 binding.
Abstract
Premature ovarian insufficiency (POI) is a leading cause of female infertility. Its mechanisms are poorly understood, and effective therapies are lacking. In this study, we aimed to identify novel druggable targets and repurposable drugs for POI through an integrated multiomics and computational pharmacology approach. We integrated large-scale proteomic data from two independent cohorts (deCODE, N = 35,559; UK Biobank, N = 54,219) using Mendelian randomization, Bayesian colocalization, and single-cell RNA sequencing. Seven high-confidence targets were identified: EPHA4, FSTL3, NUCB2, OXT, SERPINA12, TNFRSF6B, and FABP1. Among these genes, EPHA4, FSTL3, and NUCB2 were significantly dysregulated in cisplatin-induced mouse and human granulosa cell models (P < 0.05 to P < 0.001) and exhibited high diagnostic accuracy (AUC = 0.92-0.96), supporting their potential as both biomarkers and therapeutic targets. Molecular docking revealed strong binding affinities, notably for cycloheximide binding to EPHA4 (-7.8 kcal/mol), with molecular dynamics confirming stable interactions (root mean square deviation, RMSD < 2.0 Å), providing a structural basis for drug repurposing or lead optimization. The functional enrichment results suggested that fibrosis, inflammation, and metabolic dysregulation are involved in POI pathogenesis. Collectively, our findings establish a multiomics-to-therapy pipeline that not only prioritizes causal targets for POI but also provides translational opportunities, from biomarker-guided diagnosis to computationally driven drug repositioning, paving the way for mechanism-based interventions in ovarian aging.
Why this matters
Ovarian aging has lacked human-anchored causal targets beyond hormonal descriptors; a proteomic MR + colocalization pipeline that survives cisplatin granulosa-cell validation moves POI target discovery from association to genetically-supported causality for a small set of proteins. The docking-based repurposing leads (e.g., cycloheximide–EPHA4) are hypothesis-generation, and the gap between MR-nominated targets and any human ovarian-function readout remains wide.